Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $343M (up 13.6% year over year) with net income of $122M.
Q2 2026 key financials · XBRL
- Revenue
- $343M
- +13.6% YoY · +8.2% QoQ
- Net income
- $122M
- +577.8% YoY · +37.1% QoQ
- Operating margin
- 46.6%
- Gross margin
- 85.4%
- EPS (diluted)
- $0.98
- +600.0% YoY · +42.0% QoQ
Source: XBRL data from the Indivior Pharmaceuticals, Inc. (INDV) Q2 2026 10-Q on SEC EDGAR. USD.
Indivior Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Pending Supernus merger subject to stockholder and regulatory approvals, with completion timing uncertain
- Merger failure risk includes substantial termination fee exposure and transaction costs
- Contractual restrictions during merger could limit acquisitions, indebtedness, dividends, capital expenditures, and claim settlements
- Fixed 1.5401 exchange ratio exposes Indivior shareholders to stock-price volatility before closing
- Integration risk could prevent realization of anticipated merger synergies, growth, profitability, and earnings accretion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Indivior Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.